inject
medic
like
streptomycin
organ
resist
streptomycin
capreomycin
amikacin
chosen
possibl
least
three
oral
medic
use
along
inject
durat
therapi
least
month
inject
includ
regimen
least
first
month
therapi
toler
patient
local
diseas
cultur
convers
month
therapi
consider
given
surgic
remov
diseas
lung
treatment
regimen
patient
coinfect
hiv
although
therapi
extend
month
patient
coinfect
hiv
mdrtb
high
mortal
rate
acut
pneumonia
import
caus
morbid
mortal
worldwid
major
case
acut
commun
acquir
pneumonia
cap
due
bacteria
especi
streptococc
pneumonia
less
commonli
atyp
organ
respiratori
tract
virus
also
contribut
substanti
proport
importantli
gener
viral
pneumonia
higher
outbreak
potenti
wide
spectrum
virus
caus
viral
pneumonia
tabl
figur
rel
import
virus
depend
host
age
immun
statu
comorbid
local
epidemiolog
determin
season
influenza
virus
belong
genu
orthomyxoviru
within
famili
orthomyxovirida
envelop
virion
contain
eight
influenza
b
seven
influenza
c
segment
singl
negativestrand
rna
pleomorph
envelop
compos
two
major
antigen
glycoprotein
hemagglutinin
ha
neuraminidas
na
major
chang
antigen
protein
structur
ha
ie
antigen
shift
may
occur
lead
pandem
minor
chang
involv
small
number
amino
acid
substitut
ie
antigen
drift
lead
epidem
influenza
antigen
shift
rare
wherea
signific
antigen
drift
occur
everi
year
altogeth
differ
subtyp
ha
nine
differ
subtyp
na
identifi
influenza
virus
variou
anim
speci
tabl
current
two
subtyp
influenza
human
circul
introduct
new
subtyp
human
result
largescal
pandem
high
morbid
mortal
naiv
immun
absenc
effect
vaccin
initi
phase
outbreak
three
influenza
pandem
occur
twentieth
centuri
sever
spanish
flu
occur
global
mortal
least
million
peopl
estim
global
popul
becam
infect
half
suffer
clinic
ill
pandem
occur
caus
death
us
new
type
emerg
remain
circul
today
seri
genet
reassort
event
demonstr
traceabl
precursor
viru
caus
initi
human
outbreak
subsequ
avian
outbreak
hong
kong
event
gave
rise
domin
genotyp
z
chicken
duck
respons
region
outbreak
appear
domest
duck
southern
china
play
central
role
gener
mainten
viru
wild
bird
may
contribut
increasingli
widespread
distribut
viru
asia
virus
pandem
potenti
becom
endem
bird
region
easili
erad
greatest
concern
reassort
current
avian
strain
circul
human
porcin
influenza
virus
produc
novel
virul
readili
transmiss
human
strain
ecolog
featur
influenza
pose
tremend
threat
public
veterinari
health
region
world
clinic
featur
spectrum
human
case
shown
tabl
figur
high
fever
cough
dyspnea
major
symptom
present
gastrointestin
symptom
diarrhea
also
common
chest
radiograph
human
case
shown
figur
mani
patient
progress
multiorgan
failur
involv
lung
liver
kidney
evid
hemophagocytosi
primari
lesion
experiment
viru
macaqu
sever
necrot
bronchointerstiti
pneumonia
similar
charact
sever
found
influenza
viral
pneumonia
human
recent
report
indic
case
may
present
gastrointestin
symptom
initi
without
respiratori
symptom
rapid
progress
enceph
multiorgan
dysfunct
syndrom
subsequ
death
asymptomat
infect
may
occur
highlight
fact
poultri
worker
posit
serolog
least
one
worker
particip
cull
poultri
hong
kong
show
evid
seroconvers
without
symptom
two
class
antivir
compound
known
effect
influenza
name
channel
blocker
amantadin
rimantadin
na
inhibitor
oseltamivir
zanamivir
antivir
administr
recommend
reduc
morbid
mortal
pandem
virus
isol
recent
human
case
resist
channel
blocker
resist
may
retain
futur
pandem
strain
current
world
health
organ
us
center
diseas
control
guidelin
recommend
na
inhibitor
prefer
drug
use
influenza
pandem
oseltamivir
form
capsul
oral
suspens
readili
absorb
gut
thu
high
bioavail
least
zanamivir
form
oral
inhal
low
system
bioavail
na
inhibitor
ideal
administ
within
h
onset
symptom
dosag
recommend
usual
human
influenza
strain
shown
tabl
futur
pandem
strain
may
requir
higher
dosag
longer
durat
treatment
zanamivir
low
system
distribut
dosag
adjust
age
renal
function
requir
oseltamivir
better
system
distribut
may
advantag
case
pandem
strain
caus
signific
extrapulmonari
infect
trival
influenza
vaccin
target
circul
b
subtyp
avail
annual
vaccin
week
season
peak
recommend
risk
healthcar
worker
infect
girl
previous
contact
sick
poultri
fever
day
admiss
hospit
admiss
develop
sever
respiratori
failur
total
white
blood
cell
count
l
lymphocyt
count
l
platelet
count
l
alt
iu
l
ast
iu
l
treat
oseltamivir
admiss
die
day
later
multiorgan
failur
healthi
young
adult
age
specifi
licens
mg
inhal
daili
month
exposur
risk
long
prophylaxi
countri
safeti
efficaci
oseltamivir
prophylact
agent
children
year
age
establish
howev
may
consid
prophylact
use
group
benefit
expect
outweigh
risk
b
durat
prophylaxi
determin
intens
durat
exposur
safeti
efficaci
prophylact
administr
oseltamivir
demonstr
continu
use
drug
week
viru
respiratori
syncyti
viru
rsv
envelop
nonseg
negativestrand
rna
viru
classifi
member
genu
pneumoviru
within
famili
paramyxovirida
electron
microscopi
virion
appear
pleomorph
spheric
particl
rang
nm
diamet
morpholog
similar
paramyxovirus
includ
measl
mump
parainfluenza
virus
piv
rsv
two
antigen
subgroup
b
greater
amino
acid
homolog
role
strain
variat
epidemiolog
sever
clinic
impact
rsv
outbreak
remain
unclear
annual
season
epidem
rsv
occur
worldwid
clear
season
seen
temper
zone
peak
fall
winter
spring
tropic
subtrop
area
epidem
occur
raini
season
rsv
singl
import
caus
hospit
respiratori
tract
infect
babi
young
children
worldwid
primari
infect
occur
children
age
week
year
old
rhinorrhea
sneez
decreas
appetit
lowgrad
fever
cough
common
present
symptom
tachypnea
diffus
rhonchi
wheez
indic
involv
lower
respiratori
tract
may
follow
bronchiol
pneumonia
otiti
media
common
complic
children
recov
day
sever
case
chest
radiograph
show
featur
interstiti
pneumonia
hyperexpans
segment
lobar
consolid
peribronchi
thicken
wherea
pleural
effus
bacteri
superinfect
unusu
sever
ill
often
occur
infant
less
month
old
particularli
underli
cardiac
respiratori
diseas
prematur
infant
may
present
apneic
spell
paradox
lower
respiratori
tract
involv
common
newborn
reflect
protect
effect
matern
antibodi
studi
reveal
substanti
proport
children
sever
rsv
infect
later
decreas
pulmonari
function
recurr
cough
wheez
repeat
rsv
infect
older
children
usual
less
sever
realiz
rsv
infect
occur
commonli
healthi
adult
present
rang
asymptomat
sever
lower
respiratori
tract
infect
older
person
immunocompromis
individu
rsv
result
sever
pneumonia
acut
respiratori
distress
syndrom
ard
support
care
import
ribavirin
synthet
nucleosid
antivir
effect
rsv
vitro
administ
small
particl
aerosol
oxygen
tent
via
ventil
howev
clinic
benefit
indic
entir
clear
rsv
immunoglobulin
administ
month
clinic
benefit
prevent
sever
rsv
diseas
highrisk
children
pulmonari
cardiac
diseas
piv
belong
famili
paramyxovirida
type
pleomorph
envelop
virion
contain
nonseg
neg
singlestrand
rna
genom
surfac
glycoprotein
hemagglutinin
neuraminidas
hn
respons
attach
sialic
acid
host
cell
initi
infect
cycl
hn
togeth
anoth
envelop
protein
fusion
protein
f
mediat
fusion
viral
envelop
host
cell
plasma
membran
piv
second
lead
caus
rsv
hospit
respiratori
tract
ill
young
children
piv
transmit
droplet
produc
spectrum
clinic
ill
rang
mild
upper
respiratori
tract
infect
pharyng
otiti
media
bronchiol
sever
pneumonia
addit
syndrom
croup
character
croupi
cough
inspiratori
stridor
hoars
voic
difficulti
inspir
caus
acut
laryngotracheobronch
hallmark
present
piv
croup
mainli
seen
young
children
present
adult
document
pneumonia
uncommon
healthi
children
fatal
pneumonia
may
occur
sever
combin
immun
defici
bronchopulmonari
dysplasia
prematur
congenit
heart
diseas
follow
bone
marrow
transplant
bronchiol
obliteran
organ
pneumonia
report
longterm
sequela
extrapulmonari
infect
affect
central
nervou
system
document
ribavirin
broadspectrum
antivir
agent
inhibitori
effect
vitro
use
treat
piv
pneumonia
immunosuppress
patient
zanamivir
sialic
acid
analog
approv
treatment
influenza
also
inhibitori
effect
piv
vitro
howev
clinic
benefit
agent
remain
evalu
piv
vaccin
avail
yet
adenovirus
adv
nonenvelop
virus
icosahedr
capsid
contain
linear
doublestrand
dna
genom
differ
serotyp
human
adv
within
famili
adenovirida
serotyp
associ
lower
respiratori
tract
infect
adv
adv
adv
adv
less
commonli
adv
adv
adv
adv
adv
addit
respiratori
ill
adv
also
caus
acut
conjunct
keratoconjunct
gastroenter
hemorrhag
cystiti
mening
enceph
skin
erupt
genit
tract
infect
hepat
myocard
pericard
pancreat
rhabdomyolysi
polyarthr
rout
transmiss
adv
multipl
includ
direct
contact
droplet
aerosol
fecalor
waterborn
adv
nonenvelop
virus
resist
advers
environ
allow
readili
spread
via
fomit
ocular
instrument
adv
account
childhood
respiratori
ill
requir
hospit
major
present
clinic
featur
includ
fever
pharyng
tonsil
cough
lower
respiratori
tract
involv
pulmonari
infiltr
occur
less
half
hospit
children
hilar
lymphadenopathi
commonli
observ
chest
radiograph
compar
respiratori
virus
outbreak
acut
respiratori
diseas
due
infect
adv
adv
adv
adv
adv
militari
recruit
report
differ
part
world
case
present
third
week
train
fever
malais
nasal
congest
headach
sore
throat
cough
around
develop
patchi
pulmonari
infiltr
howev
similar
outbreak
seldom
occur
crowd
situat
dormitori
adv
frequent
isol
patient
pertussi
syndrom
primarili
caus
bordetella
pertussi
may
role
adv
syndrom
adv
may
establish
latenc
adenoid
tonsillar
tissu
follow
primari
infect
childhood
reactiv
immunosuppress
may
account
proport
sever
adenovir
diseas
observ
immunocompromis
patient
overal
fatal
rate
adenovir
pneumonia
often
multiorgan
dissemin
immunocompromis
patient
antivir
compound
use
treat
adenovir
diseas
success
experi
describ
ribavirin
treat
pneumonia
hemorrhag
cystiti
hepat
transplant
recipi
cidofovir
broadspectrum
compound
dna
virus
report
success
treat
adenovir
diseas
pediatr
hematopoiet
stem
cell
transplant
recipi
howev
effect
antivir
compound
demonstr
random
control
trial
yet
avail
live
oral
vaccin
use
us
militari
recruit
product
vaccin
ceas
adv
vaccin
avail
gener
popul
genu
metapneumoviru
classifi
within
famili
paramyxovirida
human
metapneumoviru
hmpv
known
human
viru
genu
first
recogn
hmpv
share
basic
properti
rsv
belong
subfamili
pneumovirina
transmiss
hmpv
probabl
similar
rsv
mainli
droplet
fomit
hmpv
ubiquit
infect
occur
commonli
young
children
annual
season
peak
occur
winter
month
moder
climat
zone
occur
late
spring
earli
summer
subtrop
virtual
children
serolog
evid
infect
age
year
infect
mild
cough
rhinorrhea
fever
exacerb
asthma
hmpv
account
lower
respiratori
tract
ill
children
percent
adult
coinfect
rsv
postul
caus
sever
diseas
adult
hmpv
predominantli
caus
mild
upper
respiratori
tract
infect
infect
frail
elderli
immunocompromis
produc
sever
diseas
fatal
pneumonia
associ
hmpv
report
children
adult
leukemia
well
previous
healthi
adult
genu
hantaviru
classifi
within
famili
bunyavirida
hantavirus
lipidenvelop
singlestrand
rna
virus
rodent
speci
natur
host
sourc
human
infect
hantavirus
hantavirus
associ
rang
nephrit
hepat
diseas
asia
europ
respiratori
form
diseas
manifest
hantaviru
pulmonari
syndrom
hp
mainli
seen
america
hantaviru
infect
associ
domest
occup
recreat
activ
bring
human
contact
infect
rodent
usual
rural
set
transmiss
occur
dri
materi
contamin
rodent
excreta
disturb
inhal
directli
introduc
broken
skin
conjunctiva
possibl
ingest
contamin
food
water
person
visit
laboratori
infect
rodent
hous
infect
minut
exposur
anim
hold
area
hp
typic
start
influenzalik
ill
high
fever
myalgia
asthenia
prodrom
period
day
dyspnea
respiratori
failur
hemodynam
instabl
appear
radiolog
hp
present
pulmonari
interstiti
edema
without
rapid
progress
airspac
diseas
central
bibas
distribut
pleural
effus
common
featur
occasion
pulmonari
manifest
may
occur
oligur
phase
renal
failur
present
pulmonari
edema
cardiomegali
without
pleuropericardi
effus
hantavirus
known
caus
hp
us
carri
new
world
mice
rat
famili
murida
subfamili
sigmodontina
subfamili
sigmodontina
contain
least
speci
mice
rat
widespread
north
south
america
wild
rodent
gener
associ
urban
environ
howev
speci
eg
deer
mous
whitefoot
mous
may
enter
human
habit
rural
suburban
area
associ
hantavirus
rodent
reservoir
warrant
recommend
minim
exposur
wild
rodent
mortal
hp
treat
intraven
ribavirin
appear
slightli
lower
treat
conserv
use
methylpredniso
lone
associ
dramat
decreas
mortal
viru
sever
acut
respiratori
syndrom
sar
newli
emerg
diseas
due
infect
novel
coronaviru
sarscov
first
recogn
erad
summer
known
return
sarscov
new
member
famili
coronavirida
cov
envelop
virus
larg
posit
singlestrand
genom
sarscov
appear
origin
wild
anim
reservoir
mainland
china
cov
almost
ident
sar
patient
identifi
mask
palm
civet
paguma
larvata
raccoon
dog
nyctereut
procyonoid
also
much
higher
seropreval
sarscov
among
wild
anim
handler
compar
control
guangdong
southern
china
rout
transmiss
sarscov
predominantli
close
persontoperson
contact
via
respiratori
droplet
evid
suggest
sar
might
spread
airborn
transmiss
rapidli
evolv
commun
outbreak
privat
residenti
complex
hong
kong
air
sampl
obtain
room
occupi
sar
patient
swab
taken
frequent
touch
surfac
room
nurs
station
hospit
toronto
test
posit
sarscov
rna
polymeras
chain
reaction
estim
mean
incub
period
day
mean
time
symptom
onset
hospit
vari
day
outbreak
adult
major
clinic
featur
includ
persist
fever
chillsrigor
myalgia
malais
dri
cough
headach
dyspnea
wateri
nonbloodstain
diarrhea
common
present
develop
subsequ
within
first
week
respiratori
failur
major
complic
sar
least
half
patient
requir
supplement
oxygen
acut
phase
patient
progress
ard
requir
invas
mechan
ventilatori
support
present
sar
children
similar
upper
respiratori
infect
due
virus
clinic
cours
sar
children
mild
lymphopenia
lowgrad
dissemin
intravascular
coagul
thrombocytopenia
prolong
activ
partial
thromboplastin
time
elev
ddimer
elev
lactat
dehydrogenas
ldh
creatinin
phosphokinas
cpk
common
laboratori
featur
sar
howev
retrospect
studi
toronto
shown
laboratori
variabl
except
absolut
neutrophil
count
de
monstrat
fair
poor
discriminatori
abil
distinguish
sar
caus
cap
radiograph
featur
sar
resembl
found
caus
cap
figur
distinct
radiograph
featur
sar
includ
predomin
involv
lung
peripheri
lower
zone
cavit
hilar
lymphadenopathi
pleural
effus
characterist
absent
groundglass
opacif
sometim
consolid
interlobular
septal
intralobular
interstiti
thicken
predominantli
peripher
lower
lobe
involv
commonli
reveal
highresolut
comput
tomographi
owe
limit
understand
new
diseas
treatment
sar
empir
outbreak
ribavirin
combin
proteas
inhibitor
lopinavirritonavir
initi
therapi
associ
lower
death
rate
treatment
ribavirin
alon
system
steroid
may
play
role
minim
immunemedi
lung
injuri
occur
later
phase
diseas
wherea
use
interferon
plu
corticosteroid
associ
improv
oxygen
satur
rapid
resolut
radiograph
lung
opac
lower
level
cpk
sar
patient
success
exampl
use
convalesc
plasma
favor
outcom
report
picornavirida
larg
viru
famili
includ
two
genera
rhinoviru
enteroviru
associ
respiratori
tract
infect
rhinovirus
enterovirus
small
nonenvelop
singl
positivestrand
rna
virus
virus
resist
advers
environment
condit
transmit
readili
direct
contact
fomit
compar
respiratori
virus
figur
serial
chest
radiograph
male
sever
acut
respiratori
syndrom
present
fever
cough
mild
dyspnea
day
ill
onset
mild
right
lower
zone
infiltr
develop
acut
respiratori
distress
syndrom
ard
day
b
follow
puls
steroid
intens
care
support
mark
improv
day
c
rhinoviru
infect
import
caus
acut
nasopharyng
often
refer
common
cold
repeat
rhinoviru
infect
common
sever
episod
occur
individu
within
year
larg
number
serotyp
hundr
typespecif
immun
enterovirus
also
contribut
respiratori
tract
infect
major
respiratori
tract
infect
caus
picornavirus
self
limit
signific
morbid
occur
set
complic
includ
otiti
media
sinus
exacerb
asthma
chronic
respiratori
disord
eg
chronic
obstruct
pulmonari
diseas
copd
lower
respiratori
tract
involv
without
secondari
bacteri
pneumonia
common
elderli
copd
highrisk
group
prone
sever
potenti
fatal
lower
respiratori
infect
due
picornavirus
includ
infant
bronchopulmonari
dysplasia
patient
cystic
fibrosi
sever
immunosuppress
associ
bone
marrow
organ
transplant
infect
human
immunodefici
viru
interferon
investig
treat
common
cold
high
cost
advers
effect
local
bleed
preclud
gener
use
recent
data
suggest
potenti
therapeut
applic
solubl
form
rhinoviru
receptor
intercellular
adhes
molecul
measl
viru
member
genu
morbilliviru
within
famili
paramyxovirida
envelop
viru
nonseg
neg
singlestrand
rna
genom
measl
ubiquit
common
childhood
febril
rash
ill
vaccin
era
typic
clinic
present
includ
fever
conjunct
malais
sneez
congest
rhiniti
cough
pathognomon
koplik
spot
seen
buccal
mucosa
distinct
maculopapular
rash
begin
ear
forehead
spread
face
neck
trunk
extrem
rash
reach
peak
respiratori
symptom
start
subsid
complic
otiti
media
bacteri
pneumonia
rel
rare
giant
cell
pneumonia
lifethreaten
complic
measl
seen
immunocompromis
patient
character
giant
cell
format
squamou
metaplasia
bronchiolar
epithelia
atyp
measl
occur
individu
receiv
incomplet
measl
vaccin
prior
exposur
natur
infect
pattern
exanthema
differ
skin
rash
first
develop
extrem
spread
often
becom
purpur
vesicular
urticari
patient
develop
lobular
segment
pneumonia
pleural
effus
recoveri
respiratori
symptom
slow
chest
radiograph
abnorm
remain
detect
month
pathogenesi
probabl
immunemedi
compon
result
preexist
lowlevel
measl
antibodi
viru
famili
herpesvirida
compris
eight
member
caus
infect
human
herp
simplex
viru
hsv
type
varicellazost
viru
vzv
epsteinbarr
viru
ebv
cytomegaloviru
cmv
human
herpesviru
human
herpesviru
kaposi
sarcomaassoci
herpesviru
human
herpesvirus
except
ubiquit
primari
infect
follow
lifelong
latenc
episod
reactiv
respiratori
tract
primari
site
infect
herpesvirus
herpesvir
pneumonia
rare
healthi
individu
risk
varicella
pneumonia
healthi
children
healthi
adult
primari
vzv
infect
chickenpox
pregnant
women
incid
increas
common
smoker
vzv
pneumonia
occur
day
onset
rash
clinic
featur
includ
dri
cough
dyspnea
tachypnea
chest
pain
hemoptysi
cyanosi
treatment
highdos
intraven
acyclovir
indic
pneumonia
common
caus
vzvassoci
death
herpesvir
pneumonia
occur
sever
immunocompromis
patient
hsv
pneumonia
part
potenti
fatal
dissemin
infec
tion
occur
newborn
heavili
immunosuppress
transplant
recipi
treatment
acyclovir
indic
cmv
pneumon
lifethreaten
complic
seen
allograft
recipi
mortal
paradox
acquir
immunodefici
syndrom
aid
patient
develop
sever
cmv
pneumon
despit
fact
sever
cmv
diseas
enter
retin
adren
common
explain
pathogenesi
cmv
pneumon
immunemedi
compon
treatment
cmv
pneumon
requir
combin
antivir
ganciclovir
immunoglobulin
cmv
hyperimmun
globulin
human
normal
immunoglobulin
also
associ
sever
fatal
pneumon
hemopoiet
stem
cell
transplant
recipi
suscept
ganciclovir
foscarnet
cidofovir
vitro
optim
treatment
pneumon
clear
